The Italian Rare Pancreatic Exocrine Cancer Initiative
暂无分享,去创建一个
E. Vasile | S. Barni | V. Mazzaferro | F. di Costanzo | G. Brandi | A. Scarpa | F. Giuliante | C. Luchini | R. Lawlor | I. Cataldo | S. Tommasi | A. Mangia | P. Marchetti | C. Doglioni | E. Maiello | M. Milella | C. Cella | R. Berardi | S. Cascinu | D. Santini | M. Scartozzi | S. Lonardi | G. Aprile | F. De Vita | O. Brunetti | N. Silvestris | S. Delfanti | Antonella Argentiero | A. Casadei Gardini | A. Argentiero
[1] E. Vasile,et al. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis , 2018, Pancreas.
[2] S. Tommasi,et al. Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets , 2018, Expert opinion on therapeutic targets.
[3] R. Eils,et al. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response , 2017, Clinical Cancer Research.
[4] L. Wood,et al. Pancreatic undifferentiated carcinoma with osteoclast‐like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma , 2017, The Journal of pathology.
[5] D. Ribatti,et al. Angiogenesis in adenosquamous cancer of pancreas , 2017, Oncotarget.
[6] Shivashankar H. Nagaraj,et al. Whole-genome landscape of pancreatic neuroendocrine tumours , 2017, Nature.
[7] A. Scarpa,et al. Pancreatic Ductal Adenocarcinoma and Its Variants. , 2016, Surgical pathology clinics.
[8] G. Fontanini,et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D , 2016, The Journal of pathology.
[9] L. Cantley,et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion , 2016, Nature.
[10] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[11] R. Eils,et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma , 2016, Nature Medicine.
[12] P. Allavena,et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy , 2015, Gut.
[13] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[14] Rita T Lawlor,et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas , 2014, The Journal of pathology.
[15] M. Wachtel,et al. Osteoclastic giant cell tumor of the pancreas☆ , 2014, International journal of surgery case reports.
[16] C. Sigel,et al. Cytomorphologic and immunophenotypical features of acinar cell neoplasms of the pancreas , 2013, Cancer cytopathology.
[17] T. George,et al. Characteristics and outcomes of adenosquamous carcinoma of the pancreas. , 2013, Gastrointestinal cancer research : GCR.
[18] A. Vanoli,et al. Clinicopathologic Study of 62 Acinar Cell Carcinomas of the Pancreas: Insights Into the Morphology and Immunophenotype and Search for Prognostic Markers , 2012, The American journal of surgical pathology.